Co-diagnostics, inc. jv cosara receives clearance from indian regulators for hepatitis c viral load test

Salt lake city , april 19, 2022 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx) (the "company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that cosara diagnostics pvt ltd ("cosara," or the "jv"), its joint venture for manufacturing and sales in india, has received clearance by the central drugs standard control organization ("cdsco") in india to manufacture and sell its saraq™ hepatitis c ("hcv") viral load kit as an in vitro diagnostic ("ivd"). cosara's new real-time hcv pcr test is built on the company's patented coprimer™ technology and designed to be used as an aid in assessing response to antiviral treatments in patients diagnosed with hcv, a disease with no effective vaccine that leads to nearly 300,000 deaths in 2019 according to the world health organization ("who").
CODX Ratings Summary
CODX Quant Ranking